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Serum oestradiol 17,B was measured
throughout the menstrual cycle in 40 normal
women, in 17 with fibroadenosis, in 12 with
cystic disease and in 10 with cancer of the
breast, by radioimmunoassay (Cameron and
Jones, Steroids, 1972, 20, 737).
Results showed that (1) 36 of the 40
normal premenopausal women exhibited a
constant pattern, but concentrations varied
with age; (2) oestradiol was low during the
follicular phase of the normal cycle (35 3 +
4.4 pg/ml), rose to sharp pre-ovulation peak
(192-9 ± 12-7 pg/ml) and plateaued during
the luteal phase (67.3 ± 1P5 pg/ml); (3)
patients with fibroadenosis showed a con-
centration pattern not significantly different
from normal; (4) in patients with cystic
disease, concentrations were significantly
higher during the luteal phase; (5) patients
with breast cancer considered as a group
showed no consistent divergence from normal
pattern.
OESTROGEN AND ANDROGEN
RECEPTORS IN HUMAN BREAST
CANCER. E. ENGELSMAN, C. B. KORSTEN,
J. P. PERSIJN and F. J. CLETON.
Netherlands Cancer Institute, Amsterdam.
Oestrogen and androgen receptors were
determined in human breast cancer tissue
samples.
Oestrogen receptors were found in 41% of
157 primary cancers and in 46% of 84
metastatic cancers. Androgen receptors were
present in 18% of43 primary tumours and in
22% of 36 secondary lesions.
A strong correlation was found between
the presence of oestrogen receptors in meta-
static tumour tissue and the response to
endocrine therapy: 31 objective remissions
in 39 receptor positive cases and only 4
objective remissions in 45 receptor negative
cases. For androgen receptors no such
correlation was detected in a small number
of evaluable patients.
In 12 patients the presence or absence of
oestrogen receptors did not correlate with the
objective response to endocrine therapy.
Some cases had to be recorded as a failure,
when clinical improvement was present but
without measurable tumour regression. The
receptor content need not be the same in
different metastatic deposits in one patient;
this might explain some discrepancies.
OESTROGEN RECEPTORS IN
HUMAN BREAST CANCER. G.
LECLERCQ, J. C. HEUSON and W. H MATT-
HEIEM. Institut Jules Bordet, Brussels,
Belgium.
Tumour tissue samples from 166 primary
and 136 metastatic breast cancers were
analysed for oestrogen receptors. Cytosol
fractions were incubated with increasing
amounts of 3H-oestradiol-17/3 (LeClercq et al.
Eur. J. Cancer, 1973, 9, 665). Unbound
radioactivity was removed by charcoal-
dextran. Receptors were detected in 72% of
the primary and 54% of the metastatic
tumours. In 86% ofthe " positive " cytosols,
the dissociation constant of the binding
reaction varied between0 5 and20 x 10-10M;
in the remaining 14% the range was from
201 to 132 x 10-10M. At the time of
mastectomy primary tumours were examined
together with the corresponding invaded
axillary lymph nodes. A statistically signi-
ficant correlation was observed between the
amounts of receptors at both sites. In
tumours the concentration of binding sites
varied from zero to 1480 femtomol/mg
protein. The distribution of the cytosols in
regard to this parameter was continuous and
inversely related to it. It is suggested that
the " positive " and " negative " cytosols
may not be qualitatively different, the latter
simply containing receptors in amounts
undetectable by the current methods. Re-
ceptors were never found in various oestrogen
non-target tissues or in sera.
PREDICTION OF RESPONSE OF
DISSEMINATED BREAST CANCER
TO ADRENALECTOMY AND OOPHO-
RECTOMY USING COMPUTER
AIDED EVALUATION OF CLINICAL
PRESENTATION. D. J. LEAPER and
J. C. HORROCKS. Leeds General Infirmary.
Difficulties in predicting response to
hormonal ablation are well known; criteria
employed to make such a distinction vary
from " clinical impression" through dis-
criminant function to more recently reported
assessments (e.g. oestrogen receptors). These
methods however are to some degree fallible,
time-consuming and difficult to perform.
An attempt to predict response to endo-
crine ablation in 100 patients using a com-
puter aided analysis of some 18 clinical signs
and symptoms has been made. Using a